Document is current
Any future updates will be listed below
-
Authors
De Magalhaes Pinheiro, Inês
Dawson, John R. D.
Calo, Nicolas https://orcid.org/0000-0002-0897-4091
Paolini-Bertrand, Marianne
Akondi, Kalyana Bharati
Tan, Gavin
Handel, Tracy M. https://orcid.org/0000-0002-2558-6138
Kufareva, Irina https://orcid.org/0000-0001-9083-7039
Hartley, Oliver https://orcid.org/0000-0002-2283-8379
-
Funding
Funding for this research was provided by:
Innosuisse – Schweizerische Agentur für Innovationsförderung
U.S. Department of Health & Human Services | National Institutes of Health (R01 GM136202, R21 AI149369, R21 AI156662, R01 GM136202)
- License Information
-
More Information
Article History
Received: 17 June 2024
Accepted: 17 July 2025
First Online: 18 August 2025
Competing interests
: I.P., N.C, M.P., K.A,. and O.H. are inventors of the CCL25 analogs described in the manuscript. The CCL25 analogs were discovered as part of a collaboration agreement between the University of Geneva and Orion Biotechnology; O.H. is a co-founder and employee of Orion Biotechnology. Technology licensed by the University of Geneva to Orion Biotechnology was used in the discovery of CCL25 analogs described in this study. T.M.H. is a cofounder of Lassogen Inc. and serves on the Scientific Advisory Boards of Abilita Bio, Abalone Bio and Aikium Inc. The terms of these arrangements have been reviewed and approved by the University of California, San Diego in accordance with its conflict-of-interest policies. The remaining authors declare no competing interests.
